Pharmacokinetic Optimization through Polymer-Based Drug Delivery Systems: From Bench to Bedside

Abstract

Pharmacokinetic optimization is fundamental to achieving therapeutic efficacy, yet many potent drug candidates fail in clinical translation due to limitations in solubility, stability, and bioavailability. Polymer-based drug delivery systems (PDDS) have emerged as transformative tools to overcome these challenges by modulating the absorption, distribution, metabolism, and excretion (ADME) characteristics of therapeutic agents. Through rational polymer design, these systems enhance solubility, protect drugs from enzymatic degradation, and provide controlled release profiles, resulting in prolonged systemic circulation and reduced dosing frequency. Advances such as PEGylation, biodegradable polymers (PLA, PLGA, PCL), and smart stimuli-responsive materials have significantly improved pharmacokinetic profiles across diverse drug classes. Moreover, polymer–drug conjugates, micelles, nanoparticles, and hydrogels enable targeted delivery, minimizing off-target effects and enhancing therapeutic index. Translational success stories, including Abraxane® and Oncaspar®, underscore the clinical impact of PDDS, though challenges persist in large-scale manufacturing, immunogenicity, and regulatory standardization. The integration of artificial intelligence, bioresponsive polymer chemistry, and personalized pharmacokinetic modeling represents the next frontier in customizable, patient-centric drug delivery. Collectively, polymer science continues to bridge the gap between molecular design and clinical application—driving the evolution of precision therapeutics from bench to bedside.